IceCure Medical Ltd. Ordinary Shares (ICCM)
IceCure Medical Ltd. is a medical technology company specializing in cryoablation solutions for minimally invasive treatment of tumors. Founded in Israel, the company develops and commercializes advanced cryoablation systems designed to precisely destroy cancerous tissues, primarily in breast, kidney, liver, and lung cancers. IceCure's innovative devices leverage liquid nitrogen and other cryogenic techniques to provide outpatient treatment options with reduced recovery times.
Company News
IceCure Medical presented its ProSense® cryoablation technology at the TME Fall Summit, highlighting a minimally invasive breast cancer treatment option. The FDA subsequently granted marketing authorization for ProSense® for treating low-risk breast cancer in patients over 70 or those unsuitable for surgery.
IceCure Medical reported stable Q1 2025 results, with revenue and gross margin slightly down year-over-year. The company submitted a post-market study plan to the FDA for its ProSense cryoablation system, a key step towards potential marketing authorization for early-stage breast cancer treatment in women aged 70 and older. IceCure is preparing f...
IceCure Medical's ProSense cryoablation system has shown promising results in treating breast cancer, with a 100% complete ablation rate and no complications in an outpatient setting. The study supports the use of cryoablation as a minimally invasive, outpatient treatment option for breast cancer patients.
CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice from T...
Use these tips for finding penny stocks to buy in 2022 The post 3 Tips for Identifying Penny Stocks With High Potential appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.